Juliana Rodrigues Beal

6PUBLICATIONS
44CO-AUTHORS
Predictive and prognostic markersMolecular targetsClinical midwiferyTumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jun 01, 2026
Tumor-Agnostic Therapies: Translating Scientific Breakthroughs Into Global Implementation.

|Mar 06, 2026
Clinical Impact and Clinicopathologic Correlations of Oncotype DX in Hormone Receptor-Positive/HER2-Negative Early Breast Cancer: Real-World Evidence From a Large Brazilian Cohort (GBECAM 0520).

Leandro Jonata de Carvalho Oliveira, Daniella Castro Araújo, Júlio Antonio Pereira de Araújo

|Jan 15, 2026
Response to trastuzumab-deruxtecan in metastatic triple-negative breast cancer with both HER2 mutation and low expression.

Caroline Dotto Amarger, Maria Isabel de Sampaio Rabello, Sofia Chaves Skaf

|Aug 28, 2024
Frequency of Deleterious Germline Variants in HER2-Low Breast Cancer Patients Using a Hereditary Multipanel Gene Testing.

Janaina Pontes Batista Cassoli, Ítalo Fernandes, Leonardo Carvalho

|Jun 26, 2024
Prognostic value of programmed cell death ligand 1 (PD-L1) expression in patients with stage III non-small cell lung cancer under different treatment types: a retrospective study.

Nicoly Marques de Castro, Fernando Moura, Aline Lury Hada

|Feb 25, 2023
Response to Abemaciclib and Immunotherapy Rechallenge with Nivolumab and Ipilimumab in a Heavily Pretreated TMB-H Metastatic Squamous Cell Lung Cancer with CDKN2A Mutation, PIK3CA Amplification and TPS 80%: A Case Report.

Douglas Dias E Silva, Guilherme Bes Borba, Juliana Rodrigues Beal

Pageof 1

Frequent Collaborators

3 joint publications

Pedro Luiz Serrano Uson Junior

2 joint publications

Rafael Kaliks

2 joint publications

Patrícia Taranto

2 joint publications

Fernando Moura